Cryoablation versus radiofrequency ablation for hepatocellular carcinoma: a systematic review and meta-analysis.

Int J HyperthermiaAug 13, 2026 (epub)
Clinical ResearchGastroenterologyOncology (Medical)General Surgery

Kui Mao, Youqing Wang, Weijun Yao et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the effectiveness and safety of cryoablation (CA) versus radiofrequency ablation (RFA) in treating hepatocellular carcinoma (HCC). Analyzing data from 7 studies involving 544 patients treated with CA and 925 with RFA, the study found that CA had a higher initial complete ablation rate and lower intraoperative pain, but no significant differences in progression-free survival or overall survival.

Key findings

  • CA was associated with a higher initial complete ablation rate compared to RFA (p = 0.04).
  • CA resulted in a lower incidence of intraoperative pain than RFA (p = 0.02).
  • No significant differences were found in progression-free survival or overall survival between CA and RFA.
  • The safety profiles of CA and RFA were comparable.

Why it matters

Understanding the comparative effectiveness and safety of CA and RFA is crucial for clinicians managing hepatocellular carcinoma, as it informs treatment decisions and patient care strategies.

Source

PubMed · PMID 42595456

Published in Int J Hyperthermia. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Gastroenterology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.